Good news! This seems to be an interesting, new approach! Cancer is history (soon)!
However, the presented research does not seem to be very fresh! The underlying article is actually a review article and not latest research.
"Childhood solid tumours are unbearably cruel: they account for more than half of cancer-associated deaths in kids under 14 in the United States and few new cancer drugs have been approved for them. Now hope is on the horizon thanks to PROTACs — short for proteolysis-targeting chimeras — laboratory-made molecules that hijack the cell’s protein-disposal machinery. PROTACs stand apart from other drugs as they eliminate proteins entirely instead of just stopping them from functioning. No PROTACs have been approved yet but some are in the final stages of testing for breast cancer, prostate cancer and leukaemia. ..."
"... laboratory-made molecules that hijack the cell’s protein-disposal machinery. Typical drugs gum up the business end of a protein to inhibit its activity. PROTACs, short for proteolysis-targeting chimeras, eliminate the protein altogether. They do this by tethering disease-associated proteins in human cells to an enzyme that tags the protein for destruction. ...
Of the roughly 3,000 proteins known to cause cancer and other diseases, drugs approved by the FDA, for example, target fewer than 700. Most of the rest are considered ‘undruggable’, because there’s no suitable pocket in which a drug can attach and block the protein’s activity. But a PROTAC merely has to grab on; the cell’s existing machinery does the rest. ..."
From the abstract:
"Patients with relapsed or refractory pediatric solid tumors have limited therapeutic options with little to no appreciable improvements in outcomes in over two decades. Adoptive cell therapy (ACT) is a promising, targeted option for patients with the potential to minimize acute and long-term toxicities.
In this review, we
(1) characterize the development and manufacture different ACT approaches used for pediatric solid tumors, and
(2) discuss the obstacles when targeting and treating solid tumors. The outcomes of the clinical applications of the various cell therapy products are also reviewed along with the future potential, including novel product development and combination therapies.
In sum, this review serves as a comprehensive review of the clinical trial results evaluating the safety, feasibility, and efficacy of novel cell therapy products in the clinic for the treatment of pediatric solid tumors and seeks to provide new insights regarding ACT successes, failures, and challenges to benefit a rapidly expanding immunotherapy field."
How protein-slayer drugs could beat some of the cruellest cancers "Momentum is building for PROTAC treatments that eliminate disease-causing proteins, including those responsible for difficult-to-treat childhood cancers."
Adoptive Cell Therapy for Pediatric Solid Tumors (no public access)
No comments:
Post a Comment